



WORLD CONGRESS OF GASTROENTEROLOGY AND DIGESTIVE DISEASES



Nebojsa Manojlovic

Military Medical Academy, Serbia

Pancreatic Adenocarcinoma

Abstract: Pancreatic ductal adenocarcinoma (PDAC), which is notorious for its aggressiveness and poor prognosis, remains an area of great unmet medical need, with a 5-year survival rate of 10%—the lowest of all solid tumours. At diagnosis, only 20% of patients have resectable (RPC) or borderline resectable disease (BRPC), while 80% of patients have unresectable tumours that are locally advanced (LAPC) or have distant metastases. Nearly 60% of patients who undergo upfront surgery for RPC are unable to receive adequate adjuvant chemotherapy because of postoperative complications and early cancer recurrence. An important paradigm shift to achieve better outcomes has been the sequence of therapy, with neoadjuvant chemotherapy preceding surgery. Three surgical stages have emerged for the preoperative assessment of nonmetastatic pancreatic cancers: RPC, BRPC and LAPC. The main goal of neoadjuvant treatment (NAT) is to improve postoperative outcomes through enhanced selection of candidates for curative-intent surgery by identifying patients with aggressive or metastatic disease during initial chemotherapy, reducing tumour volume before surgery to improve the rate of margin-negative resection (R0 resection, a microscopic margin-negative resection), reducing the rate of positive lymph node occurrence at surgery, providing early treatment of occult micrometastatic disease, and assessing tumour chemosensitivity and tolerance to treatment as potential surgical criteria. Future research is needed to establish predictive biomarkers, measures of therapeutic response, and multidisciplinary strategies to improve patient-centred outcomes.

Biography: Professor Nebojsa Manojlovic has been Head of Department of Gastroenterology and Department for Digestive Oncology in Clinic for Gastroenterology and Hepatology of Military Medical Academy in Belgrade.

After receiving his medical degree from the Medical Faculty of Belgrade University, he started with a specialization in internal medicine and postgraduate study of digestive systems in the university hospital Bezanijska Kosa in Belgrade. During a residency in internal medicine, he moved to the Institute for Oncology and Radiology of Serbia (National Cancer Research Center) and the University Clinical Center of Serbia when he finished specialization in internal medicine, got a master's degree in digestive system, finished specialization in gastroenterology and hepatology, and specialized in oncology and became a research consultant in oncology.

After that, he moved to the Clinic for Gastroenterology and Hepatology of the Military Medical Academy, where he became Head of Department for Digestive Oncology in the Military Medical Academy, where he finished his doctoral thesis and became Assistant Professor of Internal Medicine; after that, Associate Professor and Professor of Gastroenterology and Hepatology, and Digestive Oncology. He received grants from the European Society for Gastrointestinal Endoscopy and the European Society for Medical Oncology. He is serving as a reviewer of more medical journals, including the World Journal of Gastroenterology, the World Journal of Gastrointestinal Oncology, the World Journal of Gastrointestinal Endoscopy, the World Journal of Case Reports, Cancers, Gut Pathogens, and the Journal of Personalized Medicine, and a member of the editorial boards of some of them.